Last reviewed · How we verify
CG53135-05, velafermin
Velafermin is a recombinant human fibroblast growth factor 2 (FGF-2) that stimulates angiogenesis and wound healing.
Velafermin is a recombinant human fibroblast growth factor 2 (FGF-2) that stimulates angiogenesis and wound healing. Used for Diabetic foot ulcers, Venous leg ulcers.
At a glance
| Generic name | CG53135-05, velafermin |
|---|---|
| Sponsor | CuraGen Corporation |
| Drug class | Fibroblast growth factor |
| Target | FGF receptors |
| Modality | Small molecule |
| Therapeutic area | Wound healing |
| Phase | Phase 2 |
Mechanism of action
It works by promoting the formation of new blood vessels and enhancing the healing process in various tissues. This is achieved through its interaction with FGF receptors, which triggers a cascade of signaling events leading to increased angiogenesis and tissue repair.
Approved indications
- Diabetic foot ulcers
- Venous leg ulcers
Common side effects
- Injection site reactions
- Nausea
- Headache
Key clinical trials
- A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis (PHASE2)
- Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CG53135-05, velafermin CI brief — competitive landscape report
- CG53135-05, velafermin updates RSS · CI watch RSS
- CuraGen Corporation portfolio CI